Shandong Sito Bio-technology Co Ltd (SHE:300583) — Market Cap & Net Worth
Market Cap & Net Worth: Shandong Sito Bio-technology Co Ltd (300583)
Shandong Sito Bio-technology Co Ltd (SHE:300583) has a market capitalization of $339.50 Million (CN¥2.32 Billion) as of August 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #14130 globally and #4191 in its home market, demonstrating a 11.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shandong Sito Bio-technology Co Ltd's stock price CN¥12.23 by its total outstanding shares 189702126 (189.70 Million). See reinvestment intensity of Shandong Sito Bio-technology Co Ltd to understand how much of operating cash flow is reinvested back into capital assets.
Shandong Sito Bio-technology Co Ltd Market Cap History: 2017 to 2026
Shandong Sito Bio-technology Co Ltd's market capitalization history from 2017 to 2026. Data shows change from $680.34 Million to $339.50 Million (-10.29% CAGR).
Shandong Sito Bio-technology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shandong Sito Bio-technology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.56x
Shandong Sito Bio-technology Co Ltd's market cap is 0.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $680.34 Million | $785.57 Million | $92.00 Million | 0.87x | 7.39x |
| 2018 | $551.38 Million | $1.05 Billion | $126.85 Million | 0.52x | 4.35x |
| 2019 | $573.38 Million | $965.80 Million | $55.31 Million | 0.59x | 10.37x |
| 2020 | $394.34 Million | $913.19 Million | -$179.81 Million | 0.43x | N/A |
| 2021 | $413.08 Million | $1.20 Billion | $36.21 Million | 0.34x | 11.41x |
| 2022 | $381.71 Million | $1.31 Billion | $41.97 Million | 0.29x | 9.10x |
| 2023 | $530.39 Million | $1.28 Billion | $45.60 Million | 0.41x | 11.63x |
| 2024 | $542.70 Million | $970.60 Million | -$88.77 Million | 0.56x | N/A |
Competitor Companies of 300583 by Market Capitalization
Companies near Shandong Sito Bio-technology Co Ltd in the global market cap rankings as of August 4, 2026.
Key companies related to Shandong Sito Bio-technology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Shandong Sito Bio-technology Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Shandong Sito Bio-technology Co Ltd's market cap moved from $680.34 Million to $ 339.50 Million, with a yearly change of -10.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥339.50 Million | -10.66% |
| 2025 | CN¥380.03 Million | -29.97% |
| 2024 | CN¥542.70 Million | +2.32% |
| 2023 | CN¥530.39 Million | +38.95% |
| 2022 | CN¥381.71 Million | -7.60% |
| 2021 | CN¥413.08 Million | +4.75% |
| 2020 | CN¥394.34 Million | -31.23% |
| 2019 | CN¥573.38 Million | +3.99% |
| 2018 | CN¥551.38 Million | -18.95% |
| 2017 | CN¥680.34 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Shandong Sito Bio-technology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $339.50 Million USD |
| MoneyControl | $339.50 Million USD |
| MarketWatch | $339.50 Million USD |
| marketcap.company | $339.50 Million USD |
| Reuters | $339.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a me… Read more